Here we present a case study using an inhaled formulation of bevacizumab, a mAb VEGF-inhibitor formulated via spray drying. It was tested in a pre-clinical rat model of NSCLC and found to reduce tumor burden as effectively as injections.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center